Related Experiment Video
Updated: Jun 15, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Red Blood Cell Membrane Spontaneously Coated Nanoprodrug Based on Phosphatidylserine for Antiatherosclerosis
Yu Cao1, ZhiQiang Han1, Li Zhu1
1Key Laboratory for Bioarcheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400044, China.
Insights
A novel red blood cell membrane-coated nanomedicine effectively targets atherosclerosis by improving drug delivery and reducing side effects. This biomimetic approach shows significant therapeutic efficacy and biocompatibility for treating cardiovascular diseases.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Cardiovascular Medicine
Background:
- Atherosclerosis (AS) involves lipid accumulation in coronary arteries, causing narrowing and hardening, and is a primary cause of cardiovascular diseases.
- Current treatments face challenges in drug delivery and exhibit toxic side effects.
- Existing nanomedicine systems may be cleared non-specifically by the mononuclear phagocyte system, limiting their efficacy.
Purpose of the Study:
- To develop a biomimetic nanomedicine platform for enhanced anti-atherosclerosis therapy.
- To utilize a red blood cell membrane coating for improved biocompatibility and targeted delivery.
- To leverage a CLIKKPF polypeptide for spontaneous nanotherapeutic encapsulation.
Main Methods:
- Fabrication of red blood cell membrane-enveloped nanotherapeutics (RBC@P-LVTNPs) via simple coincubation with CLIKKPF polypeptide.
- Functional modification of nanotherapeutics for targeted delivery to atherosclerotic lesions.
- In vitro and in vivo evaluation of therapeutic efficacy and biocompatibility.
Main Results:
- RBC@P-LVTNPs demonstrated targeted drug delivery to atherosclerotic lesions.
- The nanomedicine responded to pathological reactive oxygen species (ROS) accumulation, enabling on-demand drug release.
- Both in vitro and in vivo studies confirmed significant therapeutic efficacy and favorable biocompatibility.
Conclusions:
- The developed biomimetic nanomedicine system offers a promising approach for atherosclerosis treatment.
- Red blood cell membrane encapsulation enhances biocompatibility and targeted drug delivery.
- This platform provides a potential nanotherapeutic strategy against atherosclerosis with improved efficacy and safety.
Abstract:
Atherosclerosis (AS) is characterized by the accumulation of lipids within the walls of coronary arteries, leading to arterial narrowing and hardening. It serves as the primary etiology and pathological basis for cardiovascular diseases affecting the heart and brain. However, conventional pharmacotherapy is constrained by inadequate drug delivery and pronounced toxic side effects. Moreover, the inefficacy of nanomedicine delivery systems in controlling disease progression may be attributed to nonspecific clearance by the mononuclear phagocyte system. Thus, a biomimetic platform spontaneously enveloped by red blood cell membrane is exploited for anti-atherosclerosis applications, offering favorable biocompatibility. The CLIKKPF polypeptide is introduced to develop red blood cell membrane spontaneously encapsulated nanotherapeutics only through simple coincubation. Given the functional modifications, RBC@P-LVTNPs is beneficial to facilitate the target drug delivery to the atherosclerotic lesion, responding precisely to the pathological ROS accumulation, thereby accelerating the on-demand drug release. Both in vivo and in vitro results also confirm the significant therapeutic efficacy and favorable biocompatibility of the biomimetic nanomedicine delivery system, thus providing a promising candidate for nanotherapeutics against AS.
More Related Videos
08:01Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
